Clinical Trials

Are you an adult with atrial fibrillation? In this study, researchers are comparing a continuous direct oral anticoagulation (DOAC) use versus time-limited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) for persons with atrial fibrillation and a moderate risk of stroke. Participants must be between the ages of 22 and 85 and have a history of atrial fibrillation. The study is taking place at locations in California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Texas, Virginia, Wisconsin, and Washington, D.C.

Are you at least 18 years old and have scheduled elective valve surgery? You may be able to participate in a study where researchers are investigating whether a type of gene therapy can help prevent a form of atrial fibrillation that occurs after surgery. The study is taking place in Worcester, Massachusetts.

Do you know someone who will be having heart surgery? This study aims to identify what genetic patterns might cause atrial fibrillation and other adverse events that happen after heart surgery. To participate in this study, you must be between 20 and 90 years old. The study is in three locations in Massachusetts and Texas.

Did you develop atrial fibrillation after coronary artery bypass graft (CABG) surgery? Did you develop atrial fibrillation after a coronary artery bypass grafting (CABG) surgery? This study is looking at how well oral anticoagulation medicines work to prevent complications, such as blood clots and heart attack, for patients who experience post-operative atrial fibrillation (POAF). This study is in multiple locations around the country.

Do you have COPD? This study will be looking for genes that may play a role in the development of COPD by looking at the blood from patients who have COPD, as well as the blood from those patients’ family members. To participate in this study, you must be 52 years old or younger and must not be pregnant or have other serious lung diseases such as lung cancer. This study will be conducted in Boston, Massachusetts.

Are you a healthy adult or someone with a history of lung infections such as pneumonia or bronchitis? This study aims to compare fluid and tissue samples from the nose and lungs of healthy adults with people who have a lung disease. Researchers hope to learn why some people are more susceptible to certain infections. This study is located at the NIH Clinical Center in Bethesda, Maryland.

his trial will evaluate an oral drug discovered in a high throughput screen, which increases fetal globin protein (HbF and red blood cells expressing HbF)and messenger ribonucleic acid (mRNA) to high levels in anemic nonhuman primates and in transgenic mice.

Sickle Cell Disease (SCD) impairs oxygen transport to tissue and causes endothelial injury. Thus, therapeutic interventions aim to improve both, but there is an unmet need for biomarkers to determine when intervention is necessary and evaluate the effectiveness of the chosen intervention in individual patients. This study proposes to monitor SCD and its treatment through their impact on cerebral hemodynamics, as the brain is one of the most vulnerable and consequential targets of the disease. Specifically, this study will optimize quantitative magnetic resonance imaging (MRI) and advanced optical spectroscopy techniques such as frequency-domain near-infrared and diffuse correlation spectroscopies (FDNIRS-DCS) to monitor 1) cerebral oxygen transport with measures of cerebral blood flow (CBF), cerebral oxygen extraction fraction (OEF) and cerebral metabolic rate of oxygen consumption (CMRO2) and 2) endothelial function with cerebrovascular reactivity (CVR).

The main goal of this study is to determine whether the treatment will lead to a complete absence of severe vaso-occlusive events (VOEs) in patients with severe SCD.

Are you or your child at least 13 years old and have sickle cell disease? In this stidy, researchers are trying to find out if a new medication improves the success of a blood stem cell transplant. People 13 years old or older who are eligible for a blood stem cell transplant to treat sickle cell disease may be able to participate. Healthy family members over age 13 who are matched to transplant recipients are also needed to donate blood for the study. This study is taking place at the National Institutes of Health Clinical Center in Bethesda, Maryland.